As of 2026-03-30, the Relative Valuation of Travere Therapeutics Inc (TVTX) is (3.82) USD. This relative valuation is based on P/E multiples. With the latest stock price at 27.25 USD, the upside of Travere Therapeutics Inc based on Relative Valuation is -114.0%.
The range of the Relative Valuation is (2.93) - (4.81) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 18.2x | 14.5x |
| Forward P/E multiples | 9.9x - 17.4x | 13.1x |
| Fair Price | (2.93) - (4.81) | (3.82) |
| Upside | -110.8% - -117.6% | -114.0% |
| Date | P/E |
| 2026-03-27 | -98.39 |
| 2026-03-26 | -100.81 |
| 2026-03-25 | -99.51 |
| 2026-03-24 | -96.73 |
| 2026-03-23 | -100.20 |
| 2026-03-20 | -96.91 |
| 2026-03-19 | -100.09 |
| 2026-03-18 | -97.35 |
| 2026-03-17 | -100.23 |
| 2026-03-16 | -101.21 |
| 2026-03-13 | -100.38 |
| 2026-03-12 | -99.48 |
| 2026-03-11 | -102.80 |
| 2026-03-10 | -103.38 |
| 2026-03-09 | -104.64 |
| 2026-03-06 | -98.36 |
| 2026-03-05 | -98.61 |
| 2026-03-04 | -101.75 |
| 2026-03-03 | -102.08 |
| 2026-03-02 | -106.63 |
| 2026-02-27 | -107.56 |
| 2026-02-26 | -107.31 |
| 2026-02-25 | -105.94 |
| 2026-02-24 | -111.50 |
| 2026-02-23 | -110.96 |
| 2026-02-20 | -109.73 |
| 2026-02-19 | -105.79 |
| 2026-02-18 | -100.63 |
| 2026-02-17 | -103.81 |
| 2026-02-13 | -100.45 |
| 2026-02-12 | -110.49 |
| 2026-02-11 | -109.12 |
| 2026-02-10 | -109.48 |
| 2026-02-09 | -108.57 |
| 2026-02-06 | -107.28 |
| 2026-02-05 | -106.41 |
| 2026-02-04 | -114.39 |
| 2026-02-03 | -118.58 |
| 2026-02-02 | -119.50 |
| 2026-01-30 | -112.26 |
| 2026-01-29 | -115.51 |
| 2026-01-28 | -109.33 |
| 2026-01-27 | -108.43 |
| 2026-01-26 | -108.11 |
| 2026-01-23 | -106.30 |
| 2026-01-22 | -107.35 |
| 2026-01-21 | -102.00 |
| 2026-01-20 | -100.88 |
| 2026-01-16 | -100.63 |
| 2026-01-15 | -102.55 |